Ixekizumab a viable long-term treatment option for axial spondyloarthritis
A 16-week treatment course of ixekizumab proves effective in the treatment of patients with active radiographic axial spondyloarthritis (r-axSpA) who are naïve to biological disease-modifying antirheumatic drug (bDMARD) or previously exposed to tumour necrosis factor inhibitor (TNFi), with the treatment benefits persisting for up to 52 weeks, according to the 2-year extension phase data from two phase III trials—COAST-V and COAST-W.